Anavex/$AVXL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Anavex
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
Ticker
$AVXL
Sector
Primary listing
Employees
42
Headquarters
Website
Anavex Metrics
BasicAdvanced
$754M
-
-$0.57
0.80
-
Price and volume
Market cap
$754M
Beta
0.8
52-week high
$14.44
52-week low
$5.03
Average daily volume
969K
Financial strength
Current ratio
8.927
Quick ratio
8.888
Profitability
Management effectiveness
Return on assets (TTM)
-27.41%
Return on equity (TTM)
-43.64%
Valuation
Price to book
8.24
Price to tangible book (TTM)
8.24
Price to free cash flow (TTM)
-20.121
Free cash flow yield (TTM)
-4.97%
Free cash flow per share (TTM)
-0.436
Growth
Earnings per share change (TTM)
12.92%
3-year earnings per share growth (CAGR)
-1.59%
10-year earnings per share growth (CAGR)
-6.19%
What the Analysts think about Anavex
Analyst ratings (Buy, Hold, Sell) for Anavex stock.
Bulls say / Bears say
Anavex completed full enrollment of its Phase 2 ANAVEX®3-71 schizophrenia trial with 71 participants on May 1, 2025, laying groundwork for top-line data expected in the second half of 2025 (GlobeNewswire).
Open-label extension data from the Phase IIb/III ATTENTION-AD OLE trial demonstrated sustained, clinically meaningful benefits through three years of continuous blarcamesine treatment in early Alzheimer’s patients (TradingView/GlobeNewswire).
Robust liquidity with $101.2 million in cash and equivalents as of June 30, 2025, provides an approximate cash runway of more than three years (GlobeNewswire).
Cash reserves declined by over $31 million from $132.2 million at September 30, 2024 to $101.2 million at June 30, 2025, reflecting a burn rate that pressures future financing needs (GlobeNewswire).
General and administrative expenses surged to $4.5 million in Q3 FY25, up from $2.8 million a year earlier, pointing to escalating overhead costs (GlobeNewswire).
Third-quarter net loss widened to $13.2 million (−$0.16 per share) from $12.2 million (−$0.14) YoY, underscoring mounting losses as development programs advance (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
Anavex Financial Performance
Revenues and expenses
Anavex Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Anavex stock?
Anavex (AVXL) has a market cap of $754M as of September 19, 2025.
What is the P/E ratio for Anavex stock?
The price to earnings (P/E) ratio for Anavex (AVXL) stock is 0 as of September 19, 2025.
Does Anavex stock pay dividends?
No, Anavex (AVXL) stock does not pay dividends to its shareholders as of September 19, 2025.
When is the next Anavex dividend payment date?
Anavex (AVXL) stock does not pay dividends to its shareholders.
What is the beta indicator for Anavex?
Anavex (AVXL) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.